[SCHEDULE 13G] Y-mAbs Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Glazer Capital, LLC and Paul J. Glazer reported beneficial ownership of 2,654,700 shares of Y-mAbs Therapeutics, Inc. common stock, representing 5.84% of the class. The filing states that Glazer Capital (a Delaware LLC) acts as investment manager for funds and managed accounts holding the shares and that Mr. Glazer is the managing member. The reporting persons disclose shared voting and shared dispositive power over the 2,654,700 shares and no sole voting or dispositive power. The business office for the filers is listed in New York.

Positive

• Material ownership disclosed: Reporting persons clearly state a 5.84% stake (2,654,700 shares), meeting SEC disclosure requirements.
• Transparency on powers: The filing specifies shared voting and dispositive power and lists the managing member and business address.

Negative

• No sole voting or dispositive power: The reporting persons report 0 shares of sole voting or sole dispositive power, indicating no unilateral control.

Insights

Financial Analyst

TL;DR: A disclosure of a >5% stake signals a sizable investor position that could draw market attention.

The Schedule 13G reports a 5.84% position (2,654,700 shares) held via funds and managed accounts for which Glazer Capital is investment manager. This is a standard passive ownership disclosure under Rule 13d-1. The filing provides clear allocation of voting and dispositive powers as shared rather than sole, which limits interpretation of unilateral control. No acquisitions, dispositions, or intent to influence control are stated in the document.

Corporate Governance Expert

TL;DR: Shared voting/dispositive power is disclosed; the filing affirms passive intent and does not assert control.

The Schedule 13G classification and the certification language indicate the reporting persons are presenting this as non-control, passive ownership. The filing identifies the managing member and the business address, and it explicitly records 0 sole voting power and 2,654,700 shared voting/dispositive power. For governance analysis, the filing documents material ownership but does not signal any coordinated group or control actions.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Y-mAbs Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value

(Title of Class of Securities)

984241109

(CUSIP Number)

08/08/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 984241109

1

Names of Reporting Persons

Glazer Capital, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,654,700.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,654,700.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,654,700.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.84 %

12

Type of Reporting Person (See Instructions)

IA, OO

SCHEDULE 13G

CUSIP No. 984241109

1

Names of Reporting Persons

Paul J. Glazer

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 2,654,700.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 2,654,700.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,654,700.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.84 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Y-mAbs Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 202 CARNEGIE CENTER, SUITE 301, PRINCETON, NJ, 08540
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Glazer Capital, LLC, a Delaware limited liability company ("Glazer Capital"), with respect to the shares of Common Stock (as defined in Item 2(d)) held by certain funds and managed accounts to which Glazer Capital serves as investment manager (collectively, the "Glazer Funds"); and (ii) Mr. Paul J. Glazer ("Mr. Glazer"), who serves as the Managing Member of Glazer Capital, with respect to the shares of Common Stock held by the Glazer Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the Reporting Persons is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock (as defined in Item 2(d)) reported herein.
(b)	Address or principal business office or, if none, residence: The address of the business office of each of the Reporting Persons is 250 West 55th Street, Suite 30A, New York, New York 10019.
(c)	Citizenship: Glazer Capital is a Delaware limited liability company. Mr. Glazer is a United States citizen.
(d)	Title of class of securities: Common Stock, $0.0001 par value
(e)	CUSIP No.: 984241109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 2,654,700
(b)	Percent of class: 5.84%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 2,654,700
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 2,654,700
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Glazer Capital, LLC

Signature:	Paul J. Glazer
Name/Title:	Paul J. Glazer, Managing Member
Date:	08/15/2025

Paul J. Glazer

Signature:	Paul J. Glazer
Name/Title:	Paul J. Glazer
Date:	08/15/2025

FAQ

What stake in Y-mAbs (YMAB) do Glazer Capital and Paul J. Glazer report?

They report beneficial ownership of 2,654,700 shares, representing 5.84% of Y-mAbs common stock.

Do the filers claim control of Y-mAbs (YMAB)?

No. The filing is a Schedule 13G indicating passive ownership and the certification states the securities were not acquired to change or influence control.

What voting and dispositive powers are reported by the filers?

The filers report 0 sole voting power, 2,654,700 shared voting power, 0 sole dispositive power, and 2,654,700 shared dispositive power.

Where is the reporting person's business address listed?

The business office for the reporting persons is listed as 250 West 55th Street, Suite 30A, New York, NY 10019.

What form and rule is this filing made under?

This is a Schedule 13G filed under the Securities Exchange Act; the filing identifies classifications consistent with Rule 13d-1.